Kentucky is currently home to 1068 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Louisville, Lexington, Owensboro and Paducah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259
Recruiting
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/22/2025
Locations: Local Institution - 0047, Louisville, Kentucky
Conditions: Multiple Sclerosis, Relapsing-Remitting
Register for Updates
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Qualmedica Research, Bowling Green, Kentucky
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Register for Updates
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/22/2025
Locations: Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky
Conditions: Acute Myeloid Leukemias
Register for Updates
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
NCT06072131
Recruiting
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Safety): This is a 3 Arm study. Patients with previously untreated PTCL will be randomized 1:1:1 into 1 of 3 treatment groups: 2 experimental treatment groups (Bel-CHOP or Fol-COP) or 1 active comparator treatment group (CHOP). Patients will be treated for up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: Peripheral T Cell Lymphoma
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
NCT05778188
Recruiting
Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left with significant neurocognitive disability. Despite this vital unmet medical need, no pharmacological adjunct or alternative therapy has proven beneficial in improving outcomes in neonatal HIE. RLS-0071 is a novel peptide being developed for the treatment of neonatal HIE. This study is designed to e... Read More
Gender:
ALL
Ages:
10 hours and below
Trial Updated:
07/22/2025
Locations: Study Site 012, Lexington, Kentucky
Conditions: Hypoxic-Ischemic Encephalopathy
Register for Updates
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/22/2025
Locations: University of Kentucky Chandler Medical Center, Lexington, Kentucky
Conditions: Chronic Migraine
Register for Updates
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
NCT03911700
Recruiting
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of Kentucky Research Foundation, Lexington, Kentucky
Conditions: Open Midline Laparotomy
Register for Updates
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263
Recruiting
The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
Gender:
ALL
Ages:
Between 0 hours and 24 hours
Trial Updated:
07/22/2025
Locations: Norton Children's Hospital, Louisville, Kentucky
Conditions: Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
Register for Updates
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
NCT02815891
Recruiting
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
07/22/2025
Locations: University of Louisville, Louisville, Kentucky
Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Register for Updates
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
07/22/2025
Locations: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Register for Updates
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT06635785
Recruiting
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Norton Cancer Center, Louisville, Kentucky
Conditions: Advanced Solid Tumor
Register for Updates
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
NCT06523803
Recruiting
This study is being done to find out if ZW171 is safe and can treat participants with advanced (locally advanced \[inoperable\] and/or metastatic) mesothelin-expressing cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: Mesothelin-expressing Advanced Cancers
Register for Updates